SMF Street Traders Online Stock Market Trading Analysis, Videos, Commentary
February 2012 Blog Posts (2)
The Must Know Stock Market Analysis Of The Day
The markets are floating higher today after an agreement was reached on a second Greek bailout. This market float is the same light volume we have seen for almost two months now, no change based on the European news. Based on the market reaction, the bailout was fully expected and priced in. The SPDR S&P 500 ETF (NYSEARCA:SPY) is trading at $136.80, +0.39 (+0.29%).
After options expiration ended on Friday, Apple Inc. (NASDAQ:AAPL) found itself near the $500.00 level. Always…
Added by inthemoneystocks on February 21, 2012 at 1:39pm — No Comments
Facebook Craze Means Mobile Ad Stocks May Run
As Facebook prepares to go public, anything in the social networking space has seen a monster increase in value. Stocks like Linkedin Corporation (NYSE:LNKD) are jumping today, trading at $76.45, +4.08 (+5.64%). In addition, Chinese social player Renren Inc. (NYSE:RENN) is trading at $5.63, +0.62 (+12.38%). While these stocks have already run higher and are no longer plays, it is interesting to think about other sympathy plays that may run. The key is to look for the extension to the social…
ContinueAdded by inthemoneystocks on February 2, 2012 at 1:54pm — No Comments
Featured Blog Posts
Latest Blog Posts
- Will The Public be Late To The Party Again?
- Key Chart Alert: Chevron (NYSE:CVX)
- The Master Pivot Point On AAPL Revealed
- Stocks Perfectly Negate Biggest Sell Day Of 2012
- The Must Know Stock Market Analysis Of The Day
- Facebook Craze Means Mobile Ad Stocks May Run
- Financials Catch Morning Bid, Can It Last?
Most Popular Blog Posts
- European Crisis Eclipses World Markets
- S&P futures vs fair value: -12.00. Nasdaq futures vs fair value: -13.00
- The Inside Keys To Today's Market Action
- CMI Cummins beats by $0.12, beats on revs; guides FY11 revs (18.32 )
- Early Research Calls 1 -Update-
- PCYC Pharmacyclics reports CLL results from preclinical and clinical studies of its Btk inhibitor PCI-
- ARIA Ariad Pharm: REPEAT/ ARIAD's Ponatinib shows clinical evidence of improving anti-Leukemic activity in patients
Blog Topics by Tags
- stock (74)
- market (73)
- smfstreet.com (69)
- stockmarketfunding.com (47)
- stocks (46)
- smf (46)
- stockmarketfunding (15)
- news (13)
- futures (12)
- stockmarket (12)
© 2013 Created by SMFStreet.
Powered by
